O	0	7	Effects
O	8	10	of
O	11	12	a
B-intervention	13	21	physical
I-intervention	22	29	therapy
I-intervention	30	37	program
I-intervention	38	46	combined
I-intervention	47	51	with
I-intervention	52	58	manual
I-intervention	59	68	lymphatic
I-intervention	69	77	drainage
O	78	80	on
B-condition	81	89	shoulder
I-condition	90	98	function
I-condition	98	99	,
I-condition	100	107	quality
I-condition	108	110	of
I-condition	111	115	life
I-condition	115	116	,
I-condition	117	127	lymphedema
I-condition	128	137	incidence
I-condition	137	138	,
I-condition	139	142	and
I-condition	143	147	pain
O	148	150	in
O	151	157	breast
O	158	164	cancer
O	165	173	patients
O	174	178	with
O	179	187	axillary
O	188	191	web
O	192	200	syndrome
O	201	210	following
O	211	219	axillary
O	220	230	dissection
O	230	231	.

O	232	235	The
O	236	239	aim
O	240	242	of
O	243	247	this
O	248	253	study
O	254	257	was
O	258	260	to
O	261	269	evaluate
O	270	273	the
O	274	281	effects
O	282	284	of
O	285	293	physical
O	294	301	therapy
O	302	303	(
O	303	305	PT
O	305	306	)
O	307	315	combined
O	316	320	with
O	321	327	manual
O	328	337	lymphatic
O	338	346	drainage
O	347	348	(
O	348	351	MLD
O	351	352	)
O	353	355	on
O	356	364	shoulder
O	365	373	function
O	373	374	,
O	375	379	pain
O	379	380	,
O	381	391	lymphedema
O	391	392	,
O	393	400	visible
O	401	406	cords
O	406	407	,
O	408	411	and
O	412	419	quality
O	420	422	of
O	423	427	life
O	428	429	(
O	429	432	QOL
O	432	433	)
O	434	436	in
O	437	443	breast
O	444	450	cancer
O	451	459	patients
O	460	464	with
O	465	473	axillary
O	474	477	web
O	478	486	syndrome
O	487	488	(
O	488	491	AWS
O	491	492	)
O	492	493	.

O	494	496	In
O	497	501	this
O	502	513	prospective
O	513	514	,
O	515	525	randomized
O	526	531	trial
O	531	532	,
B-total-participants	533	535	41
B-eligibility	536	542	breast
I-eligibility	543	549	cancer
I-eligibility	550	558	patients
I-eligibility	559	563	with
I-eligibility	564	571	visible
I-eligibility	572	575	and
I-eligibility	576	584	palpable
I-eligibility	585	590	cords
I-eligibility	591	593	on
I-eligibility	594	597	the
I-eligibility	598	601	arm
I-eligibility	602	605	and
I-eligibility	606	612	axilla
I-eligibility	613	616	and
I-eligibility	617	618	a
I-eligibility	619	626	numeric
I-eligibility	627	633	rating
I-eligibility	634	639	scale
I-eligibility	640	641	(
I-eligibility	641	644	NRS
I-eligibility	644	645	)
I-eligibility	646	650	pain
I-eligibility	651	656	score
I-eligibility	657	659	of
I-eligibility	660	661	>
I-eligibility	661	662	3
O	663	667	were
O	668	676	randomly
O	677	685	assigned
O	686	688	to
B-control	689	691	PT
O	692	693	(
O	693	694	3
O	695	700	times
O	700	701	/
O	701	705	week
O	706	709	for
O	710	711	4
O	712	717	weeks
O	717	718	;
O	719	720	n
O	721	722	=
B-control-participants	723	725	20
O	725	726	)
O	727	730	and
O	731	733	PT
O	734	742	combined
O	743	747	with
O	748	751	MLD
O	752	753	(
O	753	754	5
O	755	760	times
O	760	761	/
O	761	765	week
O	766	769	for
O	770	771	4
O	772	777	weeks
O	777	778	;
O	779	784	PTMLD
O	784	785	;
O	786	787	n
O	788	789	=
B-intervention-participants	790	792	21
O	792	793	)
O	794	800	groups
O	800	801	.

O	802	805	MLD
O	806	809	was
O	810	819	performed
O	820	822	by
O	823	824	a
O	825	833	physical
O	834	843	therapist
O	844	847	and
O	848	851	the
O	852	860	patients
O	861	871	themselves
O	872	878	during
O	879	883	week
O	884	885	1
O	886	889	and
O	890	895	weeks
O	896	897	2
O	897	898	-
O	898	899	4
O	899	900	,
O	901	913	respectively
O	913	914	.

O	915	918	Arm
O	919	925	volume
O	925	926	,
O	927	935	shoulder
O	936	944	function
O	945	946	(
O	946	954	muscular
O	955	963	strength
O	963	964	;
O	965	971	active
O	972	977	range
O	978	980	of
O	981	987	motion
O	987	988	;
O	989	992	and
O	993	1005	disabilities
O	1006	1008	of
O	1009	1012	the
O	1013	1016	arm
O	1016	1017	,
O	1018	1026	shoulder
O	1026	1027	,
O	1028	1031	and
O	1032	1036	hand
O	1037	1038	[
O	1038	1042	DASH
O	1042	1043	]
O	1043	1044	)
O	1044	1045	;
O	1046	1049	QOL
O	1050	1051	(
O	1051	1059	European
O	1060	1072	Organization
O	1073	1076	for
O	1077	1085	Research
O	1086	1089	and
O	1090	1099	Treatment
O	1100	1102	of
O	1103	1109	Cancer
O	1110	1114	Core
O	1115	1118	and
O	1119	1125	Breast
O	1126	1132	Cancer
O	1132	1133	-
O	1133	1141	Specific
O	1142	1145	QOL
O	1146	1160	questionnaires
O	1160	1161	)
O	1161	1162	,
O	1163	1166	and
O	1167	1171	pain
O	1172	1173	(
O	1173	1176	NRS
O	1176	1177	)
O	1178	1182	were
O	1183	1191	assessed
O	1192	1194	at
O	1195	1203	baseline
O	1204	1207	and
O	1208	1213	after
O	1214	1215	4
O	1216	1221	weeks
O	1222	1224	of
O	1225	1234	treatment
O	1234	1235	.

B-outcome	1236	1239	QOL
I-outcome	1240	1249	including
I-outcome	1250	1260	functional
I-outcome	1261	1264	and
I-outcome	1265	1272	symptom
I-outcome	1273	1280	aspects
O	1280	1281	,
B-outcome	1282	1290	shoulder
I-outcome	1291	1297	flexor
I-outcome	1298	1306	strength
O	1306	1307	,
B-outcome	1308	1312	DASH
O	1312	1313	,
O	1314	1317	and
B-outcome	1318	1321	NRS
I-outcome	1322	1328	scores
O	1329	1333	were
O	1334	1347	significantly
O	1348	1356	improved
O	1357	1359	in
O	1360	1364	both
O	1365	1371	groups
O	1372	1377	after
O	1378	1381	the
O	1382	1383	4
O	1383	1384	-
O	1384	1388	week
O	1389	1401	intervention
O	1402	1403	(
O	1403	1404	P
O	1405	1406	<
O	1407	1408	0
O	1408	1409	.
O	1409	1411	05
O	1411	1412	)
O	1412	1413	.

B-outcome	1414	1417	NRS
I-outcome	1418	1423	score
O	1424	1427	and
B-outcome	1428	1431	arm
I-outcome	1432	1438	volume
O	1439	1443	were
O	1444	1457	significantly
O	1458	1463	lower
O	1464	1466	in
O	1467	1470	the
O	1471	1476	PTMLD
O	1477	1482	group
O	1483	1487	than
O	1488	1490	in
O	1491	1494	the
O	1495	1497	PT
O	1498	1503	group
O	1504	1505	(
O	1505	1506	P
O	1507	1508	<
O	1509	1510	0
O	1510	1511	.
O	1511	1513	05
O	1513	1514	)
O	1514	1515	.

B-outcome	1516	1526	Lymphedema
O	1527	1530	was
O	1531	1539	observed
O	1540	1542	in
O	1543	1546	the
O	1547	1549	PT
O	1550	1551	(
O	1551	1552	n
O	1553	1554	=
B-cv-bin-abs	1555	1556	6
O	1556	1557	)
O	1557	1558	,
O	1559	1562	but
B-iv-bin-abs	1563	1566	not
O	1567	1572	PTMLD
O	1572	1573	,
O	1574	1579	group
O	1580	1581	(
O	1581	1582	P
O	1583	1584	<
O	1585	1586	0
O	1586	1587	.
O	1587	1589	05
O	1589	1590	)
O	1590	1591	.

O	1592	1594	PT
O	1595	1603	improves
O	1604	1612	shoulder
O	1613	1621	function
O	1621	1622	,
O	1623	1627	pain
O	1627	1628	,
O	1629	1632	and
O	1633	1636	QOL
O	1637	1639	in
O	1640	1646	breast
O	1647	1653	cancer
O	1654	1662	patients
O	1663	1667	with
O	1668	1671	AWS
O	1672	1675	and
O	1676	1684	combined
O	1685	1689	with
O	1690	1693	MLD
O	1694	1703	decreases
O	1704	1707	arm
O	1708	1718	lymphedema
O	1718	1719	.
